Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally …
M Choi, LK Heilbrun… - American journal of …, 2010 - journals.lww.com
Background: Pancreatic cancer ranks as the fourth leading cause of cancer death in the
United States with 5-year survival ranging from 1% to 5%. Positron emission tomography
(PET) is a metabolic imaging system that is widely used for the initial staging of cancer and
detecting residual disease after treatment. There are limited data, however, on the use of this
molecular imaging technique to assess early tumor response after treatment in pancreatic
cancer. Methods: The objective of the study was to explore the relationship of early treatment …
United States with 5-year survival ranging from 1% to 5%. Positron emission tomography
(PET) is a metabolic imaging system that is widely used for the initial staging of cancer and
detecting residual disease after treatment. There are limited data, however, on the use of this
molecular imaging technique to assess early tumor response after treatment in pancreatic
cancer. Methods: The objective of the study was to explore the relationship of early treatment …